Renhe Pharmaceutical won multiple companies for 719 million

1.

The announcement shows that Shenzhen Miura and Renhe Pharmaceutical belong to the same ultimate controlling party.

Renhe Pharmaceutical's annual report shows that in 2020, the company will achieve a total operating income of 4.

Cybelan's inquiry found that these seven companies have different business scopes, covering a wide range of fields, including cosmetics, skin care products, medical equipment, food, maternal and child products, and Chinese herbal medicines

In fact, as one of the top 100 companies in China's pharmaceutical industry, Renhe Pharmaceutical has been developing across the border for a long time, and even in 2020, Renhe Pharmaceutical has achieved great success in the field of cross-border hair loss prevention

Renhe Pharmaceuticals stated that after the final completion of the acquisition with the 7 companies, it will help optimize its strategic layout, conform to its own long-term development plan, and meet the interests of all shareholders and the company

2.

Driven by policies such as consistency evaluation and volume procurement, the purchase price of drugs is much lower than the original market price

He believes that for pharmaceutical companies, under the current conditions, if they do their best to develop new drugs, they will have to pay huge costs, and there are certain risks and difficulties

In recent years, the state has continuously introduced policies to encourage the development of the big health field

According to data from the National Bureau of Statistics, preliminary calculations show that the gross domestic product in the first quarter was 24,931 billion yuan, a year-on-year increase of 18.

3.

Large-scale pharmaceutical companies have the advantages of abundant natural capital reserves and diversified industrial lines, but are there opportunities for development of small and medium-sized enterprises under the cross-border wave

With a large number of pharmaceutical companies entering the big health field, success will inevitably lead to failure.
For example, Yunnan Baiyao toothpaste can clearly identify its own position from the beginning and develop successfully
.
After all, there are not many companies .

This person believes that the core of the successful cross-border development of pharmaceutical companies is whether they can develop the market around their own advantages
.
The auxiliary role is important, but if it deviates from the main direction, no matter how good other marketing is, it will fail
.
For pharmaceutical companies, to maintain their own development advantages, it is still necessary to return to the main business of pharmaceutical companies and choose products related to their own companies.
If they are engaged in medical beauty products, they may have advantages in entering this industry.
No, it may be difficult to reflect core values
.